The world affected with HIV is reaching trillions where the treatment for HIV especially with Pregnant Women is of current trends which hit the target successfully aiming with Progression. The main objective of this study is to describe the current trends in treating the HIV during Pregnancy and changes in Socio-demography among Pregnant Women with HIV over the past years.
The group of data Collected from the National Program on Surveillance on Antiretroviral Treatment in Pregnancy in Italy says that the changes were found and analysed in antiretroviral treatment, population characteristics, maternal immune-virologic status and new-born clinical parameters. A total of 981 HIV-infected mothers who delivered between the recent years of about 2008- 2015 were evaluated. The ratio of women receiving at least three antiretroviral drugs at delivery increased significantly from 63.0% into 95.5% in 2012–2014, paralleled by a similar upward trend in the proportion of women who achieved complete viral suppression at third.
The co-formulation of zidovudine plus lamivudine remained the most common nucleoside backbone in pregnancy, even if a significant increase in the use of tenofovir plus emtricitabine was observed in more recent years. Starting from 2003, nevirapine prescription declined, paralleled by a significant rise in the use of protease inhibitors (PI), which were present in more than 60% of regimens administered in recent years. Nelfinavir was progressively replaced by ritonavir-boosted PIs, mainly lopinavir. No significant changes in preterm delivery, Apgar score, birth weight, and birth defects were observed during the study period, and the rate of HIV transmission remained below 2%. These data demonstrate a significant evolution in the treatment of HIV in pregnancy. Constant improvements in the rates of HIV suppression were observed, probably driven by the adoption of stronger and more effective regimens and by the increasing options available for combination treatment.
No comments:
Post a Comment